Uploaded July 2026 | Updated September 2026, 13 minutes ago
"Cancer tried to do away with me, and cancer research stopped it."
When Gary Wight was diagnosed with stage IV pancreatic cancer in 2024, he was told he might have just two to three months to live.
Then he enrolled in a clinical trial evaluating a new medication for his cancer.
Today, Gary is sharing why cancer research means so much to him. The trial he joined is studying a targeted drug that has nearly doubled survival for people with metastatic pancreatic cancer—a breakthrough that is changing what may be possible for patients facing this disease.
Gary's story is a powerful reminder that every clinical trial is built on years of research and made possible by patients who choose to participate, helping advance cancer care for future generations.
Watch Gary's story, then tell us: Why does cancer research matter to you?
Share your answer in the comments or record your own video using #SpeakUpForCancerResearch.
Your story could inspire others and help show why continued investment in cancer research matters.
"Cancer tried to do away with me, and cancer research stopped it."
When Gary Wight was diagnosed with stage IV pancreatic cancer in 2024, he was told he might have just two to three months to live.
Then he enrolled in a clinical trial evaluating a new medication for his cancer.
Today, Gary is sharing why cancer research means so much to him. The trial he joined is studying a targeted drug that has nearly doubled survival for people with metastatic pancreatic cancer—a breakthrough that is changing what may be possible for patients facing this disease.
Gary's story is a powerful reminder that every clinical trial is built on years of research and made possible by patients who choose to participate, helping advance cancer care for future generations.
Watch Gary's story, then tell us: Why does cancer research matter to you?
Share your answer in the comments or record your own video using #SpeakUpForCancerResearch.
Your story could inspire others and help show why continued investment in cancer research matters.
